Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C15H14O5 |
| Molecular Weight | 274.2687 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC(=O)O[C@H](C1)\C=C\C2=CC=C3OCOC3=C2
InChI
InChIKey=GTEXBOVBADJOQH-FWEMWIAWSA-N
InChI=1S/C15H14O5/c1-17-12-7-11(20-15(16)8-12)4-2-10-3-5-13-14(6-10)19-9-18-13/h2-6,8,11H,7,9H2,1H3/b4-2+/t11-/m0/s1
| Molecular Formula | C15H14O5 |
| Molecular Weight | 274.2687 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 1 |
| Optical Activity | UNSPECIFIED |
Methysticin is a kavalactone originally found in Piper methysticum (kava plant). Methysticin exhibits neuroprotective, neuromodulatory, and antifungal activities. Methysticin may also display anti-inflammatory benefit, inhibiting activation of NF-κB in lung adenocarcinoma tissue. Methysticin activates Nrf2 in neurons and astroglia, protecting against amyloid-β (Aβ)-induced neurotoxicity. This compound displays antimicrobial efficacy against species of Fusarium, Trichoderma, and Colletotrichum. Additionally, methysticin inhibits peak amplitude of voltage-gated Na+ channels in hippocampal neurons. Methysticin administration activates the Nrf2 pathway and reduces neuroinflammation, hippocampal oxidative damage and memory loss in a mouse model of AD. Therefore, kavalactones might be suitable candidates to serve as lead compounds for the development of a new class of neuroprotective drugs.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2231 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21908763 |
|||
Target ID: CHEMBL2094258 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19716299 |
|||
Target ID: CHEMBL3622 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15185840 |
0.9 µM [IC50] | ||
Target ID: CHEMBL340 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15185840 |
1.5 µM [IC50] | ||
Target ID: CHEMBL2039 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9832350 |
670.0 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2401103 |
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28448946
Mice: Treatment of transgenic APP/Psen1 mice (n=6) was started at an
age of 25 weeks and lasted for 27 weeks. The animals were treated once
a week with 6 mg/kg bodyweight methysticin.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7630425
In a concentration-range from 10 to 100 uM methysticin reversibly blocked epileptiform activity in in vitro rat seizure models.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:34:30 GMT 2025
by
admin
on
Mon Mar 31 19:34:30 GMT 2025
|
| Record UNII |
M832AIJ6HX
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
DSLD |
2592 (Number of products:13)
Created by
admin on Mon Mar 31 19:34:30 GMT 2025 , Edited by admin on Mon Mar 31 19:34:30 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
m7484
Created by
admin on Mon Mar 31 19:34:30 GMT 2025 , Edited by admin on Mon Mar 31 19:34:30 GMT 2025
|
PRIMARY | Merck Index | ||
|
DTXSID5033674
Created by
admin on Mon Mar 31 19:34:30 GMT 2025 , Edited by admin on Mon Mar 31 19:34:30 GMT 2025
|
PRIMARY | |||
|
C076881
Created by
admin on Mon Mar 31 19:34:30 GMT 2025 , Edited by admin on Mon Mar 31 19:34:30 GMT 2025
|
PRIMARY | |||
|
5281567
Created by
admin on Mon Mar 31 19:34:30 GMT 2025 , Edited by admin on Mon Mar 31 19:34:30 GMT 2025
|
PRIMARY | |||
|
495-85-2
Created by
admin on Mon Mar 31 19:34:30 GMT 2025 , Edited by admin on Mon Mar 31 19:34:30 GMT 2025
|
PRIMARY | |||
|
METHYSTICIN
Created by
admin on Mon Mar 31 19:34:30 GMT 2025 , Edited by admin on Mon Mar 31 19:34:30 GMT 2025
|
PRIMARY | |||
|
112158
Created by
admin on Mon Mar 31 19:34:30 GMT 2025 , Edited by admin on Mon Mar 31 19:34:30 GMT 2025
|
PRIMARY | |||
|
M832AIJ6HX
Created by
admin on Mon Mar 31 19:34:30 GMT 2025 , Edited by admin on Mon Mar 31 19:34:30 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT |